India Starts New Survey On Spurious Drugs
This article was originally published in PharmAsia News
Executive Summary
India continues to move ahead with efforts to tighten regulatory oversight in the pharmaceutical segment, and is working on a new countrywide survey to determine the extent of spurious and "not of standard quality" drugs which expects to sample around 47,000 products across the country.